SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ANIP

Ani Pharmaceuticals Inc (NASDAQ:ANIP)

US · Delayed Price · Currency is USD
Healthcare · Drug Manufacturers - Specialty & Generic
$68.55-$0.58 (-0.84%)
 
Market cap
$1.56B
Insider Score
Health Score
Analyst consensus
Listed since
May 5, 2000
Market Cap$1.56B-15.3%
Revenue (ttm)$1.04B+25.9%
Net Income$116.84M+206.8%
EPS$5.01+207.4%
Shares Out22.73M
PE Ratio13.23
Forward PE6.73
Dividendn/a
Ex-Dividend Daten/a
Volume227,256
Open$69.70
Previous Close$69.13
Day's Range$68.49 - $70.22
52-Week Range$67.14 - $87.76
Beta0.47
AnalystsBuy
Price Target$99.50(+45.15%)
Earnings DateFeb 26, 2027

About ANIP

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Address
104 Carnegie Center Drive, Princeton, NJ, 08540, US
Market Cap
1.56 billion
Employees
970
Industrial Classification
Drug Manufacturers - Specialty & Generic

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$3.91M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 SellAvg target $102.67 (+49.8%)

1 firm rating ANIP in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Strong
From ANIP’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-0.84%
5 Days
-4.19%
1 Month
-7.05%
6 Months
-17.13%
1 Year
-15.35%

$ANIP stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ANIP holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ANIP's directors and management

Net Shares Purchased by Insiders−30k−15k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ANIP Estimated quarterly lobbying spending

Source: U.S. Senate LDA

ANIP Revenue by Segment or Geography

$290.78MTotal
Cortrophin Gel$138.66M47.68%
Generic pharmaceutical products$104.45M35.92%
ILUVIEN and YUTIQ$22.25M7.65%
Brand royalties and other revenues$11.46M3.94%
Brands$9.98M3.43%
Other generic revenues$3.98M1.37%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New ANIP patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ANIP from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ANIP

IJRiShares Core S&P Small-Cap ETF$83.86M
AVUVAvantis U.S. Small Cap Value ETF$59.54M
VTIVanguard Morningstar Total Stock Market ETF$38.07M
IWMiShares Russell 2000 ETF$37.27M
AFTYPacer CSOP FTSE China A50 ETF$33.42M
PJPInvesco Pharmaceuticals ETF$16.88M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ANIP’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
72

News check: Q3 earnings beat with strong revenue growth, strategic $560M rare disease acquisition, and positive analyst sentiment offset by Cortrophin supply constraints and narrowing guidance.

Recent Insider Activity

Buys
0
Sells
21
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-46.0 since Aug 21
0255075100Aug 21 — Insider Score 46.0Aug 22 — Insider Score 45.0Aug 23 — Insider Score 45.0Aug 24 — Insider Score 45.0Aug 25 — Insider Score 45.0Aug 26 — Insider Score 45.0Aug 27 — Insider Score 41.0Aug 28 — Insider Score 41.0Aug 29 — Insider Score 41.0Aug 30 — Insider Score 41.0Aug 31 — Insider Score 41.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 27.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

PJPInvesco Pharmaceuticals ETF2.83%
SCAPInfrastructure Capital Small Cap Income ETF2.32%
AFSCabrdn Focused U.S. Small Cap Active ETF2.28%
XPHState Street SPDR S&P Pharmaceuticals ETF2.00%
RNINEA Series Trust - Bushido Capital US SMID Cap Equity ETF1.08%
RZGInvesco S&P SmallCap 600 Revenue ETF1.01%
NTRLFirst Trust Merger Arbitrage ETF0.90%
PSCHInvesco S&P SmallCap Health Care ETF0.75%
SFLOVictoryShares Small Cap Free Cash Flow ETF0.56%
CAFGPacer US Small Cap Cash Cows Growth Leaders ETF0.55%
JSMDJanus Henderson Small/Mid Cap Growth Alpha ETF0.50%
AIMSAcuitas Small Cap Active ETF0.42%

Weight is the stock’s share of each fund’s holdings.